A Phase 1, 2-part, Open-label, Randomized, 2-period, 2-sequence, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-986196 Phase 2 Tablet Formulation at Two Dose Levels in Healthy Adult Participants
Latest Information Update: 25 Sep 2023
At a glance
- Drugs BMS-986196 (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 19 Sep 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 15 Sep 2023 New trial record